| Literature DB >> 12953760 |
Egbert Oosterwijk1, Chaitanya R Divgi, Adrienne Brouwers, Otto C Boerman, Steven M Larson, Peter Mulders, Lloyd J Old.
Abstract
Monoclonal antibody G250 treatment may have a role in the management of metastatic RCC; however, particular subgroups who are more prone to benefit from this treatment must be delineated. High-risk patients may benefit from adjuvant treatment with this nontoxic treatment modality. Large cohort studies are needed to investigate this possibility.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12953760 DOI： 10.1016/s0094-0143(03)00028-4
Source DB: PubMed Journal: Urol Clin North Am ISSN： 0094-0143 Impact factor: 2.241